WALDENSTRÖM MACROGLOBULINEMIA (WM)
Clinical trials for WALDENSTRÖM MACROGLOBULINEMIA (WM) explained in plain language.
Never miss a new study
Get alerted when new WALDENSTRÖM MACROGLOBULINEMIA (WM) trials appear
Sign up with your email to follow new studies for WALDENSTRÖM MACROGLOBULINEMIA (WM), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to control rare blood cancer without lifelong pills
Disease control Not yet recruitingThis early-phase study tests a time-limited treatment for Waldenström macroglobulinemia, a rare blood cancer. About 21 adults will receive a sequence of ibrutinib, bendamustine, and rituximab over a few months, then stop. The goal is to find a safe dose and see if the cancer can …
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA (WM)
Phase: PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New combo aims to deepen remissions in rare blood cancer
Disease control Not yet recruitingThis study tests a combination of three drugs (zanubrutinib, a reduced dose of bendamustine, and a CD20 antibody) in 43 people with untreated Waldenström macroglobulinemia, a rare blood cancer. The goal is to see if this approach can achieve a very good partial response or better…
Matched conditions: WALDENSTRÖM MACROGLOBULINEMIA (WM)
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 11, 2026 20:38 UTC